Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.
McKesson Stock Gets A RS Rating Lift To 75 The Relative Strength (RS) Rating for McKesson stock jumped into a new percentile Wednesday, as it got a lift from 70 to 75.
Cardinal Health Stock Sees IBD RS Rating Improve To 71 In a welcome move, Cardinal Health stock saw its Relative Strength (RS) Rating rise from 65 to 71 on Friday.
Trump's Win Sends Indices To Record Highs; Financials, Small Caps Surge, Bitcoin Tops $75,000: What's Driving Markets Wednesday? An “everything rally” powered Wall Street on Wednesday after the 2024 election results, with Donald Trump emerging as the clear presidential winner.
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? 10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%
Is the Temu Hype Warranted? School's in and we've also got a look at the challenges teachers face while saving for retirement.
Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers Three major U.S. drug distributors, McKesson, Cencora, and Cardinal Health, have agreed to a $300 million settlement over claims by health insurers and benefit plans that they contributed to the opioid epidemic.
